Skip to main content

Table 1 Percentage of cell viability values

From: Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma

Cell line

Treatment modality

Concentration (μM)

Reduction in cell viability (%)

p value

NSC6539

AZ

10

6 ± 0.67

-

20

26 ± 0.87

p < 0.05

40

47 ± 0.07

p < 0.01

MS-275

0.75

12 ± 0.85

-

1.5

32 ± 0.97

p < 0.05

3

51 ± 0.23

p < 0.01

AZ + MS-275

10 + 0.75

28 ± 0.95

-

20 + 0.75

46 ± 0.56

p < 0.05

40 + 0.75

55 ± 0.50

p < 0.01

NSC6562

AZ

10

2 ± 0.07

-

20

22 ± 0.47

p < 0.05

40

45 ± 0.67

p < 0.01

MS-275

0.75

10 ± 0.34

-

1.5

24 ± 0.08

p < 0.05

3

46 ± 0.39

p < 0.01

AZ + MS-275

10 + 0.75

23 ± 0.86

-

20 + 0.75

38 ± 0.50

p < 0.05

40 + 0.75

50 ± 0.61

p < 0.01

SH-SY5Y

AZ

10

16 ± 0.20

p < 0.05

20

39 ± 0.64

p < 0.01

40

35 ± 0.58

p < 0.001

MS-275

0.75

32 ± 0.55

p < 0.001

1.5

60 ± 0.69

p < 0.001

3

86 ± 0.78

p < 0.001

AZ + MS-275

10 + 0.75

35 ± 0.85

p < 0.01

20 + 0.75

55 ± 0.86

p < 0.001

40 + 0.75

64 ± 0.78

p < 0.001

SK-N-SH

AZ

10

22 ± 0.59

p < 0.01

20

34 ± 0.42

p < 0.01

40

61 ± 0.03

p < 0.001

MS-275

0.75

37 ± 0.99

p < 0.001

1.5

66 ± 0.03

p < 0.001

3

87 ± 0.19

p < 0.001

AZ + MS-275

10 + 0.75

37 ± 0.85

p < 0.01

20 + 0.75

58 ± 0.86

p < 0.001

40 + 0.75

69 ± 0.95

p < 0.001

SK-N-BE(2)

AZ

10

15 ± 0.01

p < 0.01

20

37 ± 0.61

p < 0.01

40

61 ± 0.58

p < 0.001

MS-275

0.75

26 ± 0.69

p < 0.001

1.5

55 ± 0.38

p < 0.001

3

82 ± 0.21

p < 0.001

AZ + MS-275

10 + 0.75

34 ± 0.88

p < 0.01

20 + 0.75

52 ± 0.88

p < 0.001

40 + 0.75

62 ± 0.86

p < 0.001

  1. Table 1 shows percentage of cell viability values of NSC6539, NSC6562, SH-SY5Y, SK-N-SH and SK-N-BE(2) by AZ(0–160 μM), MS-275(0–3 μM), and AZ + MS-275 (0–160 μM + 0.75 μM) treatments (48 h)